Sidiropoulos M, Chang A, Jung K, Diamandis E P
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada.
Br J Cancer. 2001 Aug 3;85(3):393-7. doi: 10.1054/bjoc.2001.1883.
Prostate androgen regulated transcript 1 (PART-1), is a gene predominantly expressed in the prostate gland and is regulated by androgens in human prostate cancer cell lines. Here, we report additional characteristics of PART-1 tissue expression and hormonal regulation and study its expression profile in human normal and matched prostate cancer tissues. Since PART-1 shows similarity to prostate-specific antigen (PSA) in prostate specificity and regulation, we hypothesized that it may be implicated in prostate carcinogenesis or may be a potential new biomarker. We used reverse transcriptase polymerase chain reaction (RT-PCR) to further characterize PART-1 tissue expression and hormonal regulation in the LNCaP prostate cancer cell line. RT-PCR analysis revealed that PART-1 is expressed not only in the prostate and salivary gland, but also in other tissues, including the thymus and placenta. In addition to androgen stimulation, PART-1 is also up-regulated by progestins, oestrogens and glucocorticoids. We further studied the expression of PART-1 in 27 paired (from the same patient) cancerous and non-cancerous prostatic tissues, with qualitative and quantitative RT-PCR (LightCycler technology), in order to examine whether PART-1 is overexpressed or underexpressed in cancer. Our results indicated that PART-1 is more frequently overexpressed in the cancerous prostatic tissue. We conclude that this gene is overexpressed in prostate cancer and may represent a novel prostate cancer tumour marker.
前列腺雄激素调节转录本1(PART-1)是一种主要在前列腺中表达的基因,在人前列腺癌细胞系中受雄激素调节。在此,我们报告PART-1组织表达和激素调节的其他特征,并研究其在人正常和配对前列腺癌组织中的表达谱。由于PART-1在前列腺特异性和调节方面与前列腺特异性抗原(PSA)相似,我们推测它可能与前列腺癌发生有关,或者可能是一种潜在的新生物标志物。我们使用逆转录聚合酶链反应(RT-PCR)进一步表征LNCaP前列腺癌细胞系中PART-1的组织表达和激素调节。RT-PCR分析显示,PART-1不仅在前列腺和唾液腺中表达,还在其他组织中表达,包括胸腺和胎盘。除雄激素刺激外,PART-1也被孕激素、雌激素和糖皮质激素上调。我们进一步使用定性和定量RT-PCR(LightCycler技术)研究了27对(来自同一患者)癌性和非癌性前列腺组织中PART-1的表达,以检查PART-1在癌症中是过度表达还是表达不足。我们的结果表明,PART-1在癌性前列腺组织中更频繁地过度表达。我们得出结论,该基因在前列腺癌中过度表达,可能代表一种新型前列腺癌肿瘤标志物。